Mylan launches generic Fusilev

PITTSBURGH — Mylan on Tuesday announced the launch of its generic of Fusilev (levoleucovorin calcium) injection. The drug is intended for rescue use following treatment of osteosarcoma through methotrexate therapy by reducing toxicity and effect of eliminating methotrexate. It counteracts the effects of unintended overdose of folic acid antagonists.

Mylan’s version will be available in dosages of 10 mg/mL, 175 mg/17.5 mL and 250 mg/25 mL single-use vials. The drug had about $200 million in U.S. sales for the 12 months ended June 30, according to IMS Health data.